Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
ANK-dependent ATP Efflux Causes Calcium Pyrophosphate Deposition in Cartilage
1 other identifier
interventional
8
1 country
1
Brief Summary
This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for early_phase_1
Started Oct 2014
Longer than P75 for early_phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 16, 2014
CompletedFirst Posted
Study publicly available on registry
September 18, 2014
CompletedStudy Start
First participant enrolled
October 15, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 8, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 8, 2021
CompletedResults Posted
Study results publicly available
July 26, 2022
CompletedJuly 26, 2022
July 1, 2022
6.5 years
September 16, 2014
March 24, 2022
July 22, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
ATP Levels in Synovial Fluid
The investigators will measure levels of ATP in synovial fluid from patients with CPPD before and after treatment with probenecid compared to patients receiving no therapy. ATP levels are measured with a standard bioluminescent assay.
5 days
Study Arms (2)
Probenecid
EXPERIMENTALThese patients will receive 5 days of probenecid.
No intervention
NO INTERVENTIONThese patients will receive no intervention.
Interventions
Eligibility Criteria
You may qualify if:
- Age \>21 years,
- CPPD diagnosed by Ryan /McCarty criteria
- Joint effusion in a shoulder or knee
You may not qualify if:
- Inability to sign informed consent
- Age \<21 years
- History of renal stones
- Significant renal dysfunction (CKD \>stage 2)
- Blood dyscrasias
- Current use of drugs which interact with probenecid
- Concurrent gout
- Active infection, including bacteremia and overlying cellulitis
- Recent joint trauma
- Intra-articular corticosteroids in the affected joint within three months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Milwaukee, Wisconsin, 53295-1000, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Ann Rosenthal , MD ACOS/Research
- Organization
- Zablocki VA Medical Center
Study Officials
- PRINCIPAL INVESTIGATOR
Ann K Rosenthal, MD
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 16, 2014
First Posted
September 18, 2014
Study Start
October 15, 2014
Primary Completion
April 8, 2021
Study Completion
April 8, 2021
Last Updated
July 26, 2022
Results First Posted
July 26, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share